Italia - italiano - Ministero della Salute

laboratoires boiron srl -

Italia - italiano - Ministero della Salute

cemon srl -

Italia - italiano - Ministero della Salute

boiron srl -

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

genetic s.p.a. - finasteride - finasteride

Unione Europea - italiano - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - neoplasie prostatiche - terapia endocrina - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - neoplasie prostatiche - terapia endocrina - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

zentiva italia s.r.l. - finasteride - finasteride

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

ratiopharm italia srl - finasteride - compresse rivestite - "5 mg compresse rivestite con film" 15 compresse in blister pvc/pvdc/al - farmaci per l'ipertrofia prostatica